Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neuron23

Request full access

A biotech company focused on developing precision medicines for neurological and immunological diseases

South San Francisco, United StatesFounded 2018Biotech & Life Sciences

About Neuron23

Neuron23 Inc. is a clinical-stage biotechnology startup based in South San Francisco, California. The company is focused on developing precision medicines for genetically defined neurological and immunological diseases. This means they create targeted treatments for specific diseases based on the genetic makeup of the disease and the patient. Their primary market is patients suffering from these specific diseases, including Parkinson's disease.

The company operates in the biotechnology and healthcare industry, where it uses advanced technologies like data science and machine learning to discover and develop new drugs. One of their promising projects is a brain-penetrant LRRK2 inhibitor, NEU-723, which is currently in Phase 1 clinical trials. This drug is designed to treat Parkinson's disease and is paired with a first-of-its-kind diagnostic tool that helps identify patients who are likely to respond to the therapy.

Neuron23's business model revolves around the research, development, and commercialization of these precision medicines. They generate revenue through the sales of these drugs once they are approved for use. Additionally, they also collaborate with other companies, like QIAGEN, to develop companion diagnostics, which are tests used to determine the suitability of a particular treatment for a patient.

In summary, Neuron23 is a biotech startup that uses genetic information to develop targeted treatments for neurological and immunological diseases, with a focus on improving patient lives.

Source: Dealroom company data

At a glance

Status
Operational
Employees
28
Open positions
None listed
Dealroom signal
63.1/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Jun 2026 $2.5M — Michael J. Fox Foundation for Parkinson's Research ↗
SERIES DOther financing Jun 2025 $97M $500M Kleiner Perkins · Westlake Village BioPartners · SoftBank Vision Fund · Redmile Group ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Neuron23 website traffic

Latest recorded traffic for Neuron23 is 3.5K monthly website visits, up 40% over the last three months. Neuron23's team declined 20% over the past year.

Latest monthly visits3.5K 3-month web change+40% 1-year team growth-20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neuron23 in the South San Francisco ecosystem

Live from Dealroom

The Neuron23 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Michael J. Fox Foundation for Parkinson's Research

Series A8 investors entered at this stage

Series B and later5 investors entered at this stage

Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95.7%
🇬🇧 United Kingdom4.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neuron23 on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neuron23’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.